Viking Therapeutics has initiated a ~280-patient phase 2a study of oral VK2735, with management guiding for a result in H2'25. Previous trials of VK2735 have enrolled ahead of schedule ...

where x=number of monomers, usually in the thousands. It should be pointed out that when the polyethylene chain is finished growing, two Hydrogen atoms are added to 'cap' (finish) the chain ends.

WE have formulated a structure for the nucleic acids which is compatible with the main features of the X-ray diagram and with the general principles of molecular structure, and which accounts ...

In the second quarter of 2025, the business intends to start Phase 3 studies for their subcutaneous obesity therapy, VK2735. Targeting metabolic and endocrine diseases, the San Diego-based ...

Article Views are the COUNTER-compliant sum of full text article downloads since November 2008 (both PDF and HTML) across all institutions and individuals. These metrics are regularly updated to ...

CEO Brian Lian highlighted 2024 as an exceptionally busy year, with successful results from four studies, including the Phase 2 VENTURE trial for subcutaneous VK2735, which demonstrated up to 14.7 ...

Structure-based drug design is the design and optimization of a chemical structure with the goal of identifying a compound suitable for clinical testing — a drug candidate. It is based on ...

Deep generative models are rapidly becoming popular for the discovery of new molecules and materials. Such models learn on a large collection of molecular structures and produce novel compounds. In ...

Initiation of Phase 3 Studies for Subcutaneous VK2735 for Obesity Planned for 2Q25. VK2735 is a wholly owned dual agonist of the glucagon like peptide-1, or GLP-1 receptor, and the glucose ...